1-5 of 5
Ian S Mitchell
Close
Sort by
Journal Articles

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young
Journal: Blood
Blood (2022) 140 (Supplement 1): 8485–8488.
https://doi.org/10.1182/blood-2022-157343
Published: 2022
Journal Articles

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Guy Young, Steven W Pipe, Cédric Hermans, Manuel Carcao, Giancarlo Castaman, Joanna A. Davis, Jonathan M. Ducore, Amy L. Dunn, Miguel A. Escobar, Janna Journeycake, Osman Khan, Johnny Mahlangu, Shannon Meeks, Ismail Haroon Mitha, Claude Négrier, Ulrike Nowak-Göttl, Michael Recht, Tammuella Chrisentery-Singleton, Oleksandra Stasyshyn, Kateryna V. Vilchevska, Laura Villarreal Martinez, Michael Wang, Jerzy Windyga, W. Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Christopher Macie, Ian S. Mitchell, Thomas A. Wilkinson, Amy D. Shapiro
Journal: Blood
Blood (2021) 138 (Supplement 1): 3195.
https://doi.org/10.1182/blood-2021-147434
Published: 2021
Journal Articles

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

Janna M. Journeycake, MD, Cedric Hermans, MDMRCP,PhD, Jonathan M. Ducore, MD MPH, Miguel A. Escobar, MD, Guy Young, MD, Michael Wang, MD, Doris Quon, MD PhD, W Allan Alexander, MD, Ian S Mitchell, PhD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136443
Published: 2020
Journal Articles

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Steven W. Pipe, MD, Michael Recht, MD PhD, Michael U. Callaghan, MD, Robert F. Sidonio, Jr., MDMSc, Jerry Grandoni, PhD, Veronique Duretz, Daniel Bonzo, PhD, Jean Luc Plantier, PhD, Sean Evans, PhD RPh, Ian S Mitchell, PhD, Cedric Hermans, MDMRCP,PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136430
Published: 2020
Journal Articles

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Miguel A. Escobar, MD, Doris Quon, MD PhD, Cindy A. Leissinger, MD, James V Luck, Jr., MD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD, Ian S Mitchell, PhD, W Allan Alexander, MD, Cedric Hermans, MDMRCP,PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–36.
https://doi.org/10.1182/blood-2020-136448
Published: 2020